BOCA RATON, Fla. — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company focused on non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological skin conditions, announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, he will oversee global sales, marketing and commercial strategy for the company’s SRT technologies, Sentinel software and related service offerings.
The expanded responsibilities come amid a major reimbursement milestone from the Centers for Medicare & Medicaid Services, which recently established CPT codes specifically for superficial radiotherapy (SRT and IG-SRT) used to treat non-melanoma skin cancer. The development has accelerated interest across dermatology and oncology practices. As Chief Commercial Officer, Sardano will lead efforts to broaden physician adoption of SRT, strengthen recurring-revenue programs and support growth in U.S. and international markets.
“We believe we will see a notable uptick in interest for our technology, largely due to a more favorable reimbursement environment for our SRT product,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “Michael has been at the forefront of securing these wins, while supporting commercial execution around this reimbursement milestone and the future ramp in demand. His strong leadership of our sales and marketing team, combined with our deep customer relationships and best-in-class SRT outcomes over 16 years, powerfully position us to capitalize on this next phase of growth with a heightened focus on commercial strategies.”
“I’ve devoted my career to advocating the clinical and economic benefits of SRT, and I couldn’t be more excited about the latest momentum building around our technology,” said Michael Sardano. “With dedicated, clear, and favorable reimbursement now in place and an exciting new path for accelerated growth, we are redoubling our focus on expanding access to SRT nationwide and internationally so that more physicians and patients can benefit from this non-invasive, life-changing treatment. I look forward to working more closely with our outstanding commercial team to continue growing the company and advancing our mission.”
Sardano joined Sensus Healthcare in 2010 to help start the company and began full-time in 2013 as Corporate Counsel for Regulatory Affairs. He later served as Vice President and General Counsel before becoming President in 2022. He is a member of the Florida State Bar Association and holds a J.D. from New England Law and a B.S. in Management and Finance from Bentley University.
